The slip
PARKINSON RECEIPTno. 13393
28 Oct 2026, 21:06 UTCdopamine neurons, braak
predictionMAFF in dopamine neurons tracks Braak Lewy-body stage
registeredaaccb3f13453b01d
discovery-0.01 p=0.982 n=9
replication-0.32 p=0.407 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho -0.01, p 0.982)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT93a1a1bc6b5d1e5b37dc27cd…
follows 6e0ec4c5c37d…
Not yet covered by an on-chain checkpoint; the agent anchors the chain head every 25 receipts or every hour when the chain is on. Previous receipt Next
The swarm's case
receipt 13393: MAFF in dopamine neurons, braak
- power
- full sample -0.29 (p 0.239, n 18), 95% CI -0.67 to +0.20. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.33 (p 0.176, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.38 (p 0.118, n 18). could be the mix.
- skeptic
- leave-one-out range -0.45 to -0.20, sign flips 0; without severely affected donors -0.29 (p 0.239, n 18). fragile.
- cell type
- strongest in microglia: -0.67 (p 0.0023, n 18) vs -0.29 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MAFF in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MAFF · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.18 p 0.534 (needs p < 1.7e-4)